Cephalon Inc. has dropped their patent infringement suit against Actavis Inc. over a generic version of Nuvigil®, a drug for narcolepsy. The decision came after Actavis made the decision not to produce a competing version of the drug, which treats sleep apnea and shift work sleep disorder in addition to narcolepsy. Cephalon is represented by Finnegan.
Award/Ranking
June 5, 2026
Award/Ranking
Finnegan Earns Top Rankings in 2026 IAM Patent 1000 Guide; Nearly 60 Attorneys Ranked
May 28, 2026
Commentary
May 20, 2026
Award/Ranking
Associates Rank Finnegan “Best of the Best” in BTI Associate Satisfaction Survey
May 7, 2026
Announcement
Finnegan Partner Ningling Wang Becomes President of Licensing Executives Society International
May 4, 2026
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.